Sep 11, 2023 / 02:00PM GMT
Unidentified Participant
Hi. Good morning, everyone. Welcome to the H.C. Wainwright 25th Annual Global Investment Conference. For our next presentation, we have Cidara Therapeutics, and with present CEO, Jeff Stein, here with us today. Thank you for being part of a conference. Please go ahead.
Jeff Stein - Cidara Therapeutics, Inc. - President & CEO
Thomas, thank you for the introduction, and welcome everyone. As mentioned, my name is Jeff Stein, President and CEO of Cidara Therapeutics. I'm going to talk about two programs today. One more briefly, and that's our most advanced program, rezafungin, which is approved for the treatment of invasive candidiasis and candidemia. That was approved in July and is being commercialized in the US by our commercial partner, Melinta; and outside the US and outside Japan by Mundipharma.
Next catalyst in that program we expect is going to be EMA approval, which we expect in the fourth quarter of this year. One feature of all of our programs, both the rezafungin program as well as the Cloudbreak platform is that they create
Cidara Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers